NCT05454878

Brief Summary

This prospective cohort study is to investigate the incidence of atrial fibrillation after chemotherapy by aplying wearable ECG recoder and the risk factors on patients with newly diagonsed lymphoma

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 7, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 12, 2022

Completed
3 days until next milestone

Study Start

First participant enrolled

July 15, 2022

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2023

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

July 12, 2022

Status Verified

June 1, 2022

Enrollment Period

12 months

First QC Date

July 7, 2022

Last Update Submit

July 7, 2022

Conditions

Atrial Fibrillation

Keywords

lymphomachemotherapyatrial fibrillation

Outcome Measures

Primary Outcomes (1)

  • Incidence

    Incidence of atrial fibrillation after chemotherapy

    1 year after the first course of chemotherapy

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The new-onset lymphoma patient who was scheduled for chemotherapy

You may qualify if:

  • At least 18 years old;
  • Concurrent chemotherapy on patients with new-onset lymphoma: chemotherapy regimens containing anthracyclines;
  • The subject voluntarily signed the informed consent.

You may not qualify if:

  • With heart failure, acute stroke or acute coronary syndrome within 3 months before admission
  • With Atrial fibrillation on admission
  • Patient after pacemaker surgery
  • With mental illness or mentally disabled
  • Patients that the investigator considers as unsuitable for this test

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

General hospital of PLA

Beijing, Beijing Municipality, 100853, China

Location

MeSH Terms

Conditions

Atrial FibrillationLymphoma

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Yundai Chen, MD

    Chinese PLA General Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yundai Chen

CONTACT

+86 01055499135cyundai@vip.163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

July 7, 2022

First Posted

July 12, 2022

Study Start

July 15, 2022

Primary Completion

July 1, 2023

Study Completion

December 1, 2023

Last Updated

July 12, 2022

Record last verified: 2022-06

Locations

CN(1)